title: [Ciclesonid--new generation of inhaled glucocorticosteroid].
abstract: Inhaled corticosteroids with long acting beta 2-mimetics have become the mainstay of therapy for patients with asthma. The clinical and biological activity of the inhaled corticosteroids expressed as anti-inflammatory effect depends on their bioavailability, receptor affinity, lipophility, half-life terminal elimination and molecule value. Ciclesonide as a novel corticosteroid itself is inactive and used as prodrug form and needs to be cleaved by pulmonary esterases to acquire anti-inflammatory activity. Due to its quick initial activity, long clinical effectiveness in dose range of 100-800 micrograms/day, rather mild side effects, Ciclesonide is efficacious as a local potency anti-inflammatory drug.
authors.affiliation: Kliniki Chorób Wewnetrznych, Pneumonologii i Alergologii Centralnego Szpitala Klinicznego MON, Wojskowy Instytut Medyczny w Warszawie.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Chciałowski
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Płusa
mesh_terms: D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D011282:Pregnenediones / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; C120481:ciclesonide